An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

J. Hagenbeek, Thijs; R. Zbieg, Jason; Hafner, Marc; Mroue, Rana; A. Lacap, Jennifer; M. Sodir, Nicole; L. Noland, Cameron; Afghani, Shervin; Kishore, Ayush; P. Bhat, Kamakoti; Yao, Xiaosai; D. Schmidt, Stephen; Clausen, Saundra; Steffek, Micah; Lee, Wendy; Beroza, Paul; E. Martin, Scott; Lin, Eva; Fong, Rina; Di Lello, Paola; H. Kubala, Marta; N.-Y. Yang, Michelle; Lau, Jeffrey; Chan, Emily; Arrazate, Alfonso; An, Le; Levy, Elizabeth; Lorenzo, Maria; Lee, Ho-June; H. Pham, Trang; Modrušan, Zora; Zang, Richard; Chen, Yi‐Chen; Kabza, Michał; Ahmed, Musaddeque; Li, Jason; T. Chang, Matthew; Maddalo, Danilo; Evangelista, Marie; Ye, Xin; J. Crawford, James; Dey, Anwesha

doi:10.1038/s43018-023-00577-0

Public

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance

Published in Nature Cancer • Jun 5, 2023

Authors:

Thijs J. Hagenbeek

Jason R. Zbieg

Marc Hafner

Abstract

The Hippo pathway is a key growth control pathway that is conserved across species. The downstream effectors of the Hippo pathway, YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), are frequently activated in cancers to drive proliferation and survival. Based...

Subject

Hippo signaling pathway

KRAS

Allosteric regulation

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!